ZIOPHARM OncologyClinical Trials




Clinical Trials


darinaparsin (ZIO-101)» More On These Trials

Darinaparsin is a novel organic arsenic being developed for the treatment of various hematologic and solid cancers. A Phase II trial is nearing completion in patients with primary liver cancer and advanced myeloma, a Phase II trial is ongoing in patients with lymphomas, and a Phase I oral trial is in progress.

For patients and healthcare professionals interested in more information about ZIOPHARM clinical trials, please contact info@ziopharm.com or call 617-259-1983.



palifosfamide (ZIO-201)» More On These Trials

Palifosfamide (ZIO-201) is a proprietary stabilized formulation of isophosphoramide mustard (IPM), the active metabolite of ifosfamide. Palifosfamide is currently in a Phase II randomized controlled trial with doxorubicin in patients with unresectable or metastatic soft-tissue sarcoma (PICASSO trial). A single agent Phase II clinical trial in sarcoma has been completed and awaiting final data, a Phase I soft-tissue sarcoma combination trial with doxorubicin (Adriamycin®) is nearing completion, and an oral study is planned.

For patients and healthcare professionals interested in more information about ZIOPHARM clinical trials, please contact info@ziopharm.com or call 617-259-1983.



indibulin (ZIO-301)» More On These Trials

Indibulin is a novel, oral synthetic anti-mitotic agent related to but with a different mechanism than other tubulin-binding drugs that include the widely used taxanes and the vinca alkaloids. Importantly, there has been no neurotoxicity reported, a common and problematic adverse event usually associated with tubulin-binding agents. Indibulin (ZIO-301) is presently in two separate Phase I/II studies, one in combination with Tarceva® and the other in combination with Xeloda®. Composite data for indibulin’s two Phase I trials was presented in July 2008.

For patients and healthcare professionals interested in more information about ZIOPHARM clinical trials, please contact info@ziopharm.com or call 617-259-1983.
Helpful Links

© 2008 ZIOPHARM Oncology, Inc. | Privacy Policy | Terms & Conditions